<DOC>
	<DOCNO>NCT01835717</DOCNO>
	<brief_summary>Before Alzheimer 's disease ( AD ) clinical symptom appear , long period change brain occur . In long asymptomatic period preclinical phase , study population risk develop AD show cognitive difference compare control group without risk . There need short , sensitive , easily administer , reproducible , non-expensive independent socio-demographic influence test enable detection pre-symptomatic variation memory , memory decline still within normal range . Study main hypothesis : When evaluate high-demanding test memory executive function , cognitive performance cognitive healthy people age 45 65 , extensively , group 75 year , vary significantly depend clinical , socio-demographic genetic feature</brief_summary>
	<brief_title>Study Cognitive Genetic Characterization 45-65 Years Old Population</brief_title>
	<detailed_description>The purpose Study 45-65 ass : - Endogenous factor ( clinical history , risk factor , genetic factor APOE4 , etcâ€¦ ) , exogenous ( socio-demographic , ambient lifestyle variable ) cognitive reserve ( include bilingualism ) influence cognitive performance . - New and/or update test translate validated Spanish Catalan need , provide accurate sensitive measurement variability cognitive performance target population , representative preclinical phase Alzheimer 's disease . An optional visit offer study participant include : cerebral magnetic resonance , vascular ultrasound olfactory testing .</detailed_description>
	<criteria>1 . Men woman , age 45 75 year 2 . Spanish and/or Catalan speakers 3 . Agreement study procedure test : 1 . Clinical Interview questionnaire associate risk factor 2 . Cognitive test 3 . Blood sample extraction DNA analysis 4 . Close relative involvement functional evaluation volunteer 5 . Signature inform consent 1 . Cognitive impairment : MMSE &lt; 26 , MIS &lt; 6 , orientation subtest Barcelona Test II &lt; 68 , category fluency ( animal ) &lt; 12 2 . Functional status impairment : CDR &gt; 0 3 . Severe auditory and/or visual impairment 4 . Neurodevelopmental and/or psychomotor disorder 5 . Significant disease could currently interfere cognition : renal failure hemodialysis , liver cirrhosis , chronic lung disease oxygen therapy , solid organ transplantation , fibromyalgia , active cancer treatment disease investigator considers could affect participant cognition 6 . Major psychiatric disorder ( DSMIVTR ) disease could affect cognitive ability : major depression , bipolar disorder , schizophrenia dementia . 7 . Neurological disorder : Parkinson 's disease , stroke , epilepsy treatment frequent seizure ( &gt; 1/month ) past year , multiple sclerosis serious neurological disease . 8 . Brain injury interfere cognition : history head trauma parenchymal lesion extraaxial macroscopic large vessel ischemic stroke hemorrhagic stroke , brain surgery , brain tumor cause generate acquire brain damage ( cerebral chemotherapy radiotherapy ) 9 . Family history Alzheimer 's disease autosomal dominant ( 3 affect two different generation ) early onset age ( &lt; 60 year ) .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Preclinical phase Alzheimer 's disease</keyword>
	<keyword>Asymptomatic phase Alzheimer 's disease</keyword>
	<keyword>Cognitive normal</keyword>
	<keyword>Exogenous factor</keyword>
	<keyword>Endogenous factor</keyword>
	<keyword>Episodic memory test</keyword>
	<keyword>Executive function test</keyword>
	<keyword>Memory bind test validation Spanish</keyword>
	<keyword>Memory bind test validation Catalan</keyword>
</DOC>